MedTrace Logo

601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

NCT04922151 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-10

No results posted yet for this study

Summary

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

Conditions

  • Pathological Myopic Choroidal Neovascularization

Interventions

DRUG

601

intravitreal recombinant humanized anti-VEGF monoclonal antibody

DRUG

Ranibizumab

intravitreal recombinant humanized anti-VEGF monoclonal antibody

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • YouXin Chen, PHD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-04
Primary Completion
2023-01-31
Completion
2023-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922151 on ClinicalTrials.gov